EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nifuroxazide and 4-Hydroxybenzhydrazone Derivatives as New Antiparasitic (Trypanosoma cruzi and Leishmania mexicana) and Anti-Mycobacterium tuberculosis Agents

Timoteo Delgado-Maldonado iD, Diana V Navarrete-Carriola iD, Lenci K Vázquez-Jiménez iD, Alma D Paz-González, Baojie Wan, Scott Franzblau iD, Othman Mueen Mohammed iD, Lorena Rodríguez-Páez, Charmina Aguirre-Alvarado, Verónica Alcántara-Farfán, Joaquín Cordero-Martínez iD, Debasish Bandyopadhyay iD und 2 weitere

Pharmaceutics · 07.05.2025 · 17 (5) · 621

DOI: 10.3390/pharmaceutics17050621 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 07.05.2025. Verfasst von Timoteo Delgado-Maldonado und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaria de Investigacion y Posgrado del Instituto Politecnico Nacional, Secretaria de Investigación y Posgrado del Instituto Politécnico Nacional.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Nifuroxazide (Nfz) is a drug that has been used as a scaffold for designing antimicrobial and antiparasitic agents. This study aimed to synthesize and evaluate in vitro of Nfz and twenty-five 4-hydroxybenzhydrazone derivatives as potential anti-Trypanosoma cruzi, anti-Leishmania mexicana, and anti-Mycobacterium tuberculosis agents.

Methods

The compounds were synthesized by condensing 4-hydroxybenzhydrazide with appropriate aldehydes in acidic conditions and structurally confirmed by spectroscopic techniques. All compounds were evaluated in vitro against T. cruzi strains (NINOA and A1), L. mexicana (M379 and FCQEPS strains), and M. tuberculosis (H37Rv strain), followed by enzymatic assays against T. cruzi cysteine proteases.

Results

Compound Nfz-24 (IC50 = 6.8 μM) had better trypanocidal activity than the reference drugs benznidazole (IC50 > 30 μM) and nifurtimox (IC50 > 7 μM) against the NINOA strain, and Nfz-8 (IC50 = 7.2 μM) was the compound most active against the A1 strain with a high inhibition of T. cruzi cysteine proteases (IC50 = 4.6 μM) and low cytotoxic effects (CC50 >100 μM). On the other hand, compound Nfz-5 (IC50 = 5.2 μM) had a 25-fold better leishmanicidal effect than glucantime (IC50 > 125 μM) against the L. mexicana M379 strain, and compound Nfz-13 had the best leishmanicidal effects (IC50 = 10.2 μM) against the FCQEPS strain. Finally, Nfz, Nfz-1, and Nfz-2 had minimum inhibitory concentration (MIC) values of 12.3, 5.1, and 18.8 μg/mL against M. tuberculosis, respectively.

Conclusions

In summary, these results suggest that the compounds Nfz-1, Nfz-2, Nfz-5, Nfz-8, Nfz-10, Nfz-15, Nfz-24, and Nfz-25 are candidates for further studies to develop new and more potent anti-T. cruzi, anti-leishmaniasis, and anti-M. tuberculosis agents.

Schlagwörter

Stichwörter der Autor:innen

Leishmania mexicanaTrypanosoma cruzianti-Mycobacterium tuberculosiscysteine protease inhibitorshydrazone moietynifuroxazide

Autor:innen und Institutionen

  • Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
  • Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago, IL 60612, USA.
  • Department of Medical Laboratories Techniques, College of Health and Medical Technology, University of Al Maarif, Al Anbar 31001, Iraq.
  • Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
  • School of Integrative Biological and Chemical Sciences (SIBCS), University of Texas Rio Grande Valley, Edinburg, TX 78539, USA.
  • School of Earth, Environmental, and Marine Sciences (SEEMS), University of Texas Rio Grande Valley, Edinburg, TX 78539, USA.

ORCID-Profile: Timoteo Delgado-Maldonado, Diana V Navarrete-Carriola, Lenci K Vázquez-Jiménez, Scott Franzblau, Othman Mueen Mohammed, Joaquín Cordero-Martínez, Debasish Bandyopadhyay, Gildardo Rivera

Förderung

  • Secretaria de Investigacion y Posgrado del Instituto Politecnico Nacional
  • Secretaria de Investigación y Posgrado del Instituto Politécnico Nacional

Zitieren

APA

Delgado-Maldonado, T., Navarrete-Carriola, D. V., Vázquez-Jiménez, L. K., Paz-González, A. D., Wan, B., Franzblau, S., Mohammed, O. M., Rodríguez-Páez, L., Aguirre-Alvarado, C., Alcántara-Farfán, V., Cordero-Martínez, J., Bandyopadhyay, D., Moreno-Rodríguez, A., & Rivera, G. (2025). Nifuroxazide and 4-Hydroxybenzhydrazone Derivatives as New Antiparasitic (Trypanosoma cruzi and Leishmania mexicana) and Anti-Mycobacterium tuberculosis Agents. Pharmaceutics, 17(5), 621. https://doi.org/10.3390/pharmaceutics17050621

Vancouver

Delgado-Maldonado T, Navarrete-Carriola DV, Vázquez-Jiménez LK, Paz-González AD, Wan B, Franzblau S, et al. Nifuroxazide and 4-Hydroxybenzhydrazone Derivatives as New Antiparasitic (Trypanosoma cruzi and Leishmania mexicana) and Anti-Mycobacterium tuberculosis Agents. Pharmaceutics. 2025;17(5):621. doi:10.3390/pharmaceutics17050621

BibTeX
@article{DelgadoMaldonado2025,
  author = {Delgado-Maldonado, Timoteo and Navarrete-Carriola, Diana V and Vázquez-Jiménez, Lenci K and Paz-González, Alma D and Wan, Baojie and Franzblau, Scott and Mohammed, Othman Mueen and Rodríguez-Páez, Lorena and Aguirre-Alvarado, Charmina and Alcántara-Farfán, Verónica and Cordero-Martínez, Joaquín and Bandyopadhyay, Debasish and Moreno-Rodríguez, Adriana and Rivera, Gildardo},
  title = {Nifuroxazide and 4-Hydroxybenzhydrazone Derivatives as New Antiparasitic (Trypanosoma cruzi and Leishmania mexicana) and Anti-Mycobacterium tuberculosis Agents},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {5},
  pages = {621},
  doi = {10.3390/pharmaceutics17050621}
}
Kostenlos starten →